FDA Approves NARCAN Nasal Spray Multipacks for High-Volume Distribution

Emergent BioSolutions announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application for new multipack configurations of over-the-counter NARCAN Nasal Spray on Feb. 12, 2026. This approval expands the NARCAN Nasal Spray product suite to include 6-count and 24-count multipack options, specifically designed to meet the needs of partners distributing higher volumes of naloxone.

These new formats offer enhanced flexibility with the same trusted product, benefiting community programs and organizations operating large-scale, multi-site, or high-volume distribution programs. The approval will broaden the NARCAN Nasal Spray portfolio and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication.

The senior vice president, head of products business, global government and public affairs at Emergent stated that the introduction of NARCAN Nasal Spray multipacks marks a significant step in empowering partners on the front lines. They can now better streamline bulk distribution, support broad preparedness efforts, and ultimately ensure that more communities and individuals have ready access to this life-saving medication in the event of an opioid overdose emergency.

This approval builds on Emergent's ongoing commitment to enhancing NARCAN Nasal Spray accessibility and usability, complementing the recent FDA approval of the NARCAN Nasal Spray Carrying Case in January 2026. These efforts underscore Emergent's comprehensive approach to equipping individuals and organizations with effective tools to combat opioid overdose deaths.

The 6-count and 24-count multipacks will be made available soon to purchase for public interest customers through NARCANDirect, Emergent's proprietary ordering and distribution platform. These multipacks are an addition to the current portfolio and will not replace existing product formats.

Since the prescription launch of NARCAN Nasal Spray in 2016, more than 85 million doses have been distributed across the U.S. and Canada. NARCAN Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary.